Targeting multiple genetic defects of mitochondrial diseases with a single bacterial lipoate protein ligase
Science Advances · 05.12.2025 · 11 (49)
DOI: 10.1126/sciadv.aea8481 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 05.12.2025. Verfasst von Zhijuan Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center of Synthetic Biology and Integrated Bioengineering, Westlake University, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Mitochondrial Diseases, Bacterial Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National key R&D program of China, Zhejiang Key Laboratory of Low Carbon Intelligent Synthetic Biology, Competitive Research Funding Program of Center for Synthetic Biology and Integrated Bioengineering at Westlake University.
Abstract (Originalsprache)
Metabolic disorders caused by defects in energy metabolism can lead to many life-threatening diseases; their therapy remains elusive in most cases. Conventional gene therapy relies on the “one gene for one genetic defect” strategy. Here, we demonstrate a more efficient strategy to target multiple genetic defects with a single gene intervention. Specifically, we used a bacterial lipoate protein ligase involved in protein lipoylation to rescue mitochondrial dysfunctions in human lipoylation pathway ( LIPT2 , LIAS , and LIPT1 ), lipoyl precursor supply ( MECR ), and sulfur insertion accessary partner ( FDX1 ). The efficacy and safety of Escherichia coli –derived LplA or Bacillus subtilis –derived LplJ were validated in human cells and mouse models. LplA knock-in mice exhibited normal health with enhanced energy expenditure. Overexpressing LplA through a mating strategy rescued embryonic lethality in Lipt1 −/− mutants, yielding viable offspring with normal body weight, energy expenditure, tissue morphology, and biochemical profile. Our work highlights how evolutionary differences in biosynthetic pathways between humans and bacteria can be leveraged for cross-species therapeutic innovations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center of Synthetic Biology and Integrated Bioengineering, Westlake University, Hangzhou, Zhejiang, China.
- School of Engineering, Westlake University, Hangzhou, Zhejiang, China.
- Research Center for Industries of the Future, Westlake University, Hangzhou, Zhejiang, China.
- Key Laboratory of Intelligent Low-Carbon Biosynthesis of Zhejiang Province, Westlake University, Hangzhou, Zhejiang, China.
- School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China.
ORCID-Profile: Zhijuan Hu, Junru Yu, Min Jiang, An-Ping Zeng
Förderung
- National key R&D program of China
- Zhejiang Key Laboratory of Low Carbon Intelligent Synthetic Biology
- Competitive Research Funding Program of Center for Synthetic Biology and Integrated Bioengineering at Westlake University
Zitieren
APA
Hu, Z., Yu, J., Liu, Z., Jiang, M., & Zeng, A. P. (2025). Targeting multiple genetic defects of mitochondrial diseases with a single bacterial lipoate protein ligase. Science Advances, 11(49). https://doi.org/10.1126/sciadv.aea8481
Vancouver
Hu Z, Yu J, Liu Z, Jiang M, Zeng AP. Targeting multiple genetic defects of mitochondrial diseases with a single bacterial lipoate protein ligase. Science Advances. 2025;11(49). doi:10.1126/sciadv.aea8481
BibTeX
@article{Hu2025,
author = {Hu, Zhijuan and Yu, Junru and Liu, Ziwei and Jiang, Min and Zeng, An-Ping},
title = {Targeting multiple genetic defects of mitochondrial diseases with a single bacterial lipoate protein ligase},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {49},
doi = {10.1126/sciadv.aea8481}
}
EUVIMED